Mice with multiple myeloma, an incurable malignancy of the bone marrow, respond dramatically to the treatment with this drug.

These cancers include acute lymphoblastic leukaemia acute myelogenous leukaemia chronic lymphocytic leukaemia hairy cell leukaemia non Hodgkin's lymphoma Hodgkin's disease melodysplastic syndrome multiple myeloma retinoblastoma Ewing sarcoma Wilms tumour neuroblastoma sarcoma rhabdomyosarcoma testis tumour and lung cancer.

But starting in 2004, when antiangiogenic therapies first became available, well you can see that there has been a 70 to 100 percent improvement in survival for people with kidney cancer, multiple myeloma, colorectal cancer, and gastrointestinal stromal tumors.

And really this is the fourth of these molecules to kind of graduate from our little pipeline of drug discovery, two of which a topical drug for lymphoma of the skin, an oral substance for the treatment of multiple myeloma will actually come to the bedside for first clinical trial in July of this year.